KhabarAdda
Aggregated from Times of India, NDTV, Hindustan Times, India Today and more · Every source linked and credited · Updated every 15 minutes
Markets

Laurus Labs shifts gears as CDMO emerges as key growth driver; Nuvama sees 24% upside

viaeconomictimes.indiatimes.com16 Oct
Laurus Labs shifts gears as CDMO emerges as key growth driver; Nuvama sees 24% upside
Nuvama Institutional Equities has initiated coverage on Laurus Labs with a ‘Buy’ rating and a target price of Rs 2,520, implying a 24% upside from the current market price. The brokerage expects the drugmaker’s shift from its traditional anti-retroviral (ARV) business towards contract development…

Khabar Adda curates headlines like this across Top Stories, Entertainment, Bollywood, Hollywood, Crime and Politics from public RSS feeds. This page links out to economictimes.indiatimes.com's own reporting rather than reproducing it — the excerpt above comes from economictimes.indiatimes.com's own feed.

Read the full story on economictimes.indiatimes.com ↗